The U.S.-China Economic and Security Review Commission asked Congress on November 18, 2026 to create a Comprehensive Critical Drug Diversification program, or C2D2, built around U.S.-India cooperation. Its buying arm would be an HHS Federal Trusted Demand Program for essential medicines made with qualifying U.S. or trusted partner APIs and key starting materials (KSMs). Verified sourcing of those inputs would be a condition of participation. Federal procurement origin law works one tier higher. Under the Trade Agreements Act (TAA), a drug's origin turns on where the pill was made or where its active ingredient was made. No federal origin rule asks where the KSMs came from.
A tablet finished in the United States from Indian API is a U.S.-made end product, even when that API was synthesized from Chinese KSMs. A generic finished in India from Indian API is a product of India. Because India is not a designated country, that generic is generally ineligible on TAA-covered contracts at or above $174,000, whatever its KSMs. The TAA therefore screens out the India-made generics that a C2D2 program built around U.S.-India cooperation would favor. The Commission's report never mentions the TAA, so this conflict comes from reading its recommendation against the current Federal Acquisition Regulation.
For a government-contracts or trade-compliance lead at a generic manufacturer or distributor holding VA Federal Supply Schedule 65 I B or other TAA-covered drug contracts, the working file is the per-NDC origin record behind each TAA certification, which names the API country and the finishing site. C2D2 would add a third field, the KSM source, that no federal rule requires today. C2D2 remains a recommendation to Congress. Traverse found no bill implementing C2D2 or a Federal Trusted Demand Program by name as of November 18. Some India-linked drugs already qualify through exceptions, including buys below $174,000 and small business set-asides.
The Trade Agreements Act looks to the pill and its API
The FAR definition of designated country groups eligible countries into WTO GPA, free trade agreement, least developed and Caribbean Basin lists. India appears on none of them. It has been a GPA observer since February 10, 2010, not a party. For covered acquisitions, the TAA purchase restriction limits agencies to U.S.-made or designated-country end products unless such offers are not received or are insufficient. The WTO GPA threshold for supply contracts is $174,000.
CBP has long held, as in HQ H233356, that turning bulk ingredient into measured doses generally does not substantially transform it. For drugs finished abroad, that rule still assigns origin to the API country. HQ H215656 applied it to Indian tramadol tableted in France, and the product stayed Indian. Recent CBP origin rulings use the same test. Chinese API made into tablets in India was found to be of Chinese origin in N359149 and N354135. Combinations can differ. In N354437, a fixed-dose tablet of Indian bisoprolol and Chinese hydrochlorothiazide made in India became a product of India.
Finishing in the United States changes the result. In Acetris Health v. United States, the Federal Circuit held that the procured product is the pill, and that a U.S.-made end product may be made in the United States from foreign API. The same opinion noted that India is not a GPA party and has not been designated under 19 U.S.C. 2511(b), so the TAA bars products of India.
Where key starting materials drop out of the record
India supplies 35 percent of the API volume in U.S. generics, according to U.S. Pharmacopeia data and testimony the Commission cites. Repeating an estimate from its 2025 report, the Commission puts the share of U.S. generic daily doses using Indian APIs that still rely on Chinese KSMs at a quarter to nearly one-half. It adds that API and KSM origin is "typically invisible to payers, providers, patients, and even governments."
Under CBP's general substantial transformation test, synthesizing a new API from an imported KSM would likely make the API country the origin. That is an inference, since no published CBP pharmaceutical ruling squarely addresses the KSM step. FDA's amount-reporting guidance draws its line at the same tier, stating that API does not include intermediates used in its synthesis. A Senate bill, S. 5043, would add the country of origin of each API, KSM and acquired intermediate to that reporting for drugs with any such input sourced from China or another foreign country of concern. It was introduced July 21, 2026 and referred to the Committee on Health, Education, Labor, and Pensions.
Five supply routes under today's rule and a KSM test
As of November 18, 2026, this table covers TAA-covered federal supply buys at or above $174,000 outside set-asides and other subpart 25.4 exceptions. Its origin and eligibility columns reflect current FAR text, CBP rulings and Acetris, and its last column applies the USCC recommendation, which is not law. Rows assume single-API products.
| Route (KSM, API, finished dose) | Origin today | Basis | Eligible today | Likely result under a C2D2 KSM test |
|---|
| Chinese KSM, Indian API, U.S. tablet | U.S.-made end product (FAR) | Acetris, FAR 52.225-5 | Yes | Chinese KSM is not a U.S. or trusted partner input |
| Indian KSM, Indian API, Indian tablet | India | API rule, H215656, Acetris n.2 | No, absent an exception | Fits the profile if India is a trusted partner |
| Chinese KSM, Indian API, Indian tablet | India | API rule, KSM step unrecorded | No, absent an exception | Flagged for the Chinese KSM |
| Chinese API, Indian tablet | China | N359149, N354135 | No, absent an exception | Fails at the API tier |
| EU API, Indian tablet | EU member state of the API | API rule, reasoning of H215656 | Yes | Asks where the EU API's KSMs came from |
The first and third rows carry the same Chinese KSM exposure, and today the finishing site alone decides their eligibility. A KSM test would treat them alike. It would also split the second row from the third, which current origin rules treat the same.
Exceptions that already admit India-linked drugs
Below the threshold, the TAA restriction does not apply, and subpart 25.4 excludes small business set-asides, resale and several other categories.
VA also runs a non-availability lane. Its FSS 65 I B pharmaceuticals page says SIN 42-2A items that are not U.S.-made or designated-country products must be offered as other end products, and a contracting officer may make an individual non-availability determination under FAR 25.403(c). SIN 42-2A ties to the VA pricing statute, 38 U.S.C. 8126, whose covered drugs are single-source drugs, innovator multiple-source drugs and biologics, so most India-finished generics fall outside it.
What Congress or the President would have to change
A C2D2 statute could set its own eligibility rule for the HHS program, making the KSM record the test. The President could instead designate India under section 2511(b), which Acetris notes has not happened. H.R. 2213 would authorize trusted trade partner agreements for medical goods and lists increased access to government procurement markets among its purposes.
Executive action so far favors domestic supply over a trusted-partner lane. Executive Order 14336 directs API reserve purchases with a preference for domestically manufactured APIs. Proclamation 11020 left generics and their ingredients outside Section 232 tariffs for now, and the announced 2028 generic drug tariff still lacks a product identity rule. The February 6, 2026 U.S.-India joint statement covers generic tariffs and rules of origin but does not mention government procurement.
For the contracts lead, the per-NDC file can be extended now without any rule change. Record each API's KSMs by supplier and country beside the existing API and finishing-site entries, because the Commission also proposed subpoena authority to demand that documentation. The conclusion would change with bill text implementing C2D2, a 2511(b) designation of India, a U.S.-India agreement with procurement terms, movement on S. 5043, or a CBP ruling on whether KSM-to-API synthesis confers origin.